Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.

This paper described a planned clinical trial of mesenchymal stem cells, cells that may help repair or regulate body tissues. It planned to enroll 30 adults aged 60 or older who had frailty, meaning reduced strength and resilience. Participants would receive an infusion into a vein of either 100 million cells, 200 million cells, or a salt-water placebo, chosen by chance. Researchers would track safety and changes in walking ability, strength, tiredness, and inflammation for about six months.

What this means for you: This paper reports a study plan, not results, so it does not show that stem cells treat frailty. It is not a reason to buy a stem-cell treatment, especially because the study was small and experimental.